ArticleAntimicrobial agents and chemotherapy2010
GES extended-spectrum β-lactamases in Acinetobacter baumannii isolates in Belgium.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 82 citations in OpenAlex.
- Development of simplex and multiplex immunochromatographic assays for rapid detection of GES-, PER-, and VEB-producing gram-negative bacteria.Microbiology spectrum · 2026Article
- Mechanistic basis for inhibition of the extended-spectrum β-lactamase GES-1 by enmetazobactam and tazobactam.FEBS letters · 2025Article
- Phenotypic and genotypic analysis ofJAC-antimicrobial resistance · 2025Article
- Phylogenetic predictions of carbapenemase activity from the Guiana extended-spectrum (GES) family of β-lactamases.JAC-antimicrobial resistance · 2024Article
- Whole-Genome Sequencing-Based Resistome Analysis of Nosocomial Multidrug-Resistant Non-Fermenting Gram-Negative Pathogens from the Balkans.Microorganisms · 2023Review
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- Genotypic Patterns of Multidrug-ResistantAdvanced biomedical research · 2023Review
- Novel Insights intoMicrobiology spectrum · 2022Article
- Molecular Characterization of Carbapenem-ResistantInfection and drug resistance · 2022Review
- Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals.Molecular biology reports · 2021Review
- Co-Existence of Carbapenemase-Encoding Genes in Acinetobacter baumannii from Cancer Patients.Infectious diseases and therapy · 2021Article
- Molecular Epidemiology of Carbapenem-ResistantFrontiers in microbiology · 2021Article
- Molecular Epidemiology of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2020Article
- Evaluating the antimicrobial resistance patterns and molecular frequency ofNew microbes and new infections · 2020Article
- Antibiotic Susceptibility, Clonality, and Molecular Characterization of Carbapenem-Resistant Clinical Isolates ofInternational journal of microbiology · 2020Article
- Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings.Revista da Sociedade Brasileira de Medicina Tropical · 2020Review
- Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.Current infectious disease reports · 2019Review
- Dissemination of carbapenem-resistantGerms · 2019Article
- Detection of different β-lactamases encoding genes, including blaEnvironmental monitoring and assessment · 2018Article
- P174E Substitution in GES-1 and GES-5 β-Lactamases Improves Catalytic Efficiency toward Carbapenems.Antimicrobial agents and chemotherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During a PCR-based surveillance study of β-lactam resistance, 125 multidrug-resistant (MDR) Acinetobacter baumannii isolates were obtained from 18 hospitals in Belgium from January 2008 to December 2009. Nine GES-positive A. baumannii isolates were detected at 6 Belgian hospitals. DNA sequencing of the bla(GES) genes identified GES-11, GES-12, and a novel variant GES-14, which differs from GES-11 by a single amino acid substitution (Gly170Ser). All index isolates were travel associated and originated from patients transferred from Turkey (n = 2), Egypt (n = 2), and Palestinian territories (Gaza) (n = 2). A nosocomial outbreak involving three additional patients occurred in a burn unit at a single hospital. No clonal relatedness could be established between the 6 index isolates by pulsed-field gel electrophoresis (PFGE) analysis. Three different alleles (the plasmid-located bla(GES-11) and bla(GES-12) and a likely chromosomally located novel variant bla(GES-14)) were detected as part of a class 1 integron, also including the aac6'Ib and dfrA7 genes. Restriction analysis of plasmids suggests a common origin for the plasmids bearing bla(GES-11) and bla(GES-12). Cloning of the bla(GES) genes in Escherichia coli identified GES-14 as hydrolyzing imipenem, while GES-12 showed the highest specific activity against ceftazidime. This report highlights the emergence of various bla(GES-like) genes, especially those conferring carbapenem resistance in A. baumannii and its importation in Western Europe from Middle Eastern countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.